EMJ GOLD: Pharma news, views and analysis

Join Isabel and Jade as they uncover how AI is shaking up the radiology space and beyond with Naiara Martínez Cabrera, Vice President, Global Marketing, DeepHealth. Together, Naiara and Jade explore what first drew the marketing leader to the healthcare sector, why radiology in particular has seen such a boost from artificial intelligence, what other therapy areas can learn from space and much more. A little more on EMJ GOLD's guest… Naiara Martínez Cabrera is Vice President of Global Marketing, DeepHealth, where she has been since the company's inception in 2023. Prior to this appointment, she worked at Philips in roles such as Head of Communications and Head of Downstream Marketing for Precision Diagnosis.

This week, join Isabel and Jade as they explore what's on the horizon for cardiac care, focusing on the revolutionary impact of remote monitoring with Angelo Auricchio, Chief Medical Officer, Rhythm Management, Boston Scientific. He and Isabel discuss Angelo's recent career change into the industry, how technology could reform the UK's NHS, the role of remote monitoring in patient wellbeing and more. A little more on EMJ GOLD's guest… Angelo Auricchio was appointed Chief Medical Officer, Rhythm Management, Boston Scientific in September 2024, where he works across the EMEA region. Prior to his time in industry, he gained a wealth of experience in academia and medicine, serving as Editor-in-Chief of the European Society of Cardiology's journal EP Europace and President of the European Heart Rhythm Association. During his time in the medical field, he also served as Deputy Head of the Cardiology Department and Director of the Clinical Electrophysiology Unit at the Istituto Cardiocentro Ticino in Switzerland.

Join Isabel and Jade as they explore the persistent misunderstandings of women's health in modern medicine with Mary Stutts, CEO of the Healthcare Businesswomen's Association. In this episode, Mary unpacks the key findings of the HBA's latest report, which exposes critical gaps in doctors' understanding of women's health. She discusses the root causes, the real-world consequences and what the pharmaceutical industry must do to drive meaningful change. A little more on EMJ GOLD's guest… Mary is the CEO of the HBA, a global organisation with a mission is to promote the advancement and impact of women in healthcare. She is a leading voice in the industry, advocating for inclusive leadership, representative workforces and health equity. Prior to joining the HBA, she worked for Genentech, Bristol Myers Squibb, Bayer and other pharmaceutical organisations. She is also an accomplished author, having published her books 'Recurring Themes of Exclusion in the Workplace' and 'The Missing Mentor: Women Advising Women on Power, Progress and Priorities'.

Why do we forget? Join Isabel and Jade as they explore the science behind memory, recall and retention, and uncover why interactive content could be the key to making information stick. In this episode, discover how interactivity enhances learning, helps HCPs recognise the value of new therapies and ultimately improves patient care. Read our article exploring the topic further here. And if you're interested to see how interactive works in the medical context, check out the interactive article mentioned here.

Join Isabel and Jade for part two of their World Cancer Day special for 2025, where guest Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson, uncovers more of his insights into the oncology space. In this instalment, Martin shares his thoughts on improving access to innovative cancer medicines, improving public trust toward the industry and his personal leadership style. A little more on GOLD's guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson's new products and indications. Prior to this, Price worked in Johnson & Johnson's UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager.

Join Isabel and Jade as they present a special World Cancer Day 2025 edition of the podcast. They are joined by Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson. In this first instalment of the conversation, Martin and Jade discuss this year's theme 'United by Unique', the increasing importance of real-world evidence in oncology and improving access to innovative cancer medicines. A little more on GOLD's guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson's new products and indications. Prior to this, Price worked in Johnson & Johnson's UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager.

The EMJ GOLD podcast is back for a new season! In the first episode of Season 9, the team are joined by Charl van Zyl, President and CEO, Lundbeck Pharmaceuticals, to discuss advances in the treatment of neurological disorders, making this the 'decade of the brain', and how industry can do more to support patients living brain conditions. Together, Charl and Isabel explore his career journey in the pharmaceutical industry, Lundbeck's plans for the future, the role of digital health technology and much more. A little more on EMJ GOLD's guest... Charl van Zyl joined Lundbeck as President and CEO in September 2023. He brings more than 23 years of experience from commercial international management roles within the pharmaceutical industry, most recently in the field of immunology and neurology from UCB where he served as Executive Vice President and Head of Neurology globally, responsible for corporate activities in Europe and international markets. Charl is British and holds a degree in Medical Biochemistry from the University of Cape Town, South Africa. He has lived and worked in South Africa, United States, Japan, Switzerland, Belgium and now Denmark.

Curious to discover what might lie ahead for industry in 2025? Join Isabel and Jade in this special episode of the EMJ GOLD podcast as they reflect on whether last year's predictions for 2024 came true, while three special guests share their predictions and hopes for pharma in the year ahead. The line-up includes Jennifer Schranz of Ipsen, Mercedes Diz of Almirall and EMJ's own Dr Jonathan Sackier - all of whom share their predictions in their areas of expertise. A little more on GOLD's guests… Jennifer Schranz is the Senior Vice President, Global Head of Rare Diseases at Ipsen, where she oversees the Rare Diseases therapy area with a focus on R&D strategy and execution. During her time at the business, she has led talented teams of scientists and fostered strong internal collaborations within the company, leveraging her clinical development expertise to advance Ipsen's vision of addressing challenging rare diseases. Mercedes Diz has over 20 years' experience in the pharmaceutical industry, having graduated with a degree in Biochemistry and Molecular Biology from the Autonomous University of Madrid. She has worked in a number of different pharmaceutical companies, from J&J to Pfizer, and is also a keen member of the Healthcare Businesswomen's Association. At Almirall, she leads portfolio strategy and commercial innovation for global brands, new products and digital and cultural transformation. Dr Jonathan Sackier is Chairman at EMJ and the host of the EMJ podcast, where he utilises his experience as a physician to discuss the latest breakthroughs and challenges in the medical field with fellow practitioners and experts. Jonathan is a founding partner of many start-ups in the medical technology space and created the world's first operating room robot.

As 2024 comes to a close, it's time to look back on a year in the pharmaceutical industry. In this final episode of the year, Isabel and Jade are joined by three former guest to reflect on the pivotal moments that defined the past 12 months. They are joined by Jennifer Schranz from Ipsen, Martina Dempsey from Astellas and Elias Revonta, CEO of Orcason, who all return to the podcast to share their insights. Together, they'll discuss the major trends, challenges and breakthroughs that shaped 2024, including advancements in oncology, gene therapy, rare diseases and the growing role of AI. A little more on EMJ GOLD's guests... Jennifer Schranz is the Senior Vice President, Global Head of Rare Diseases at Ipsen, where she oversees the Rare Diseases therapy area with a focus on R&D strategy and execution. During her time at the business she has led talented teams of scientists and fostered strong internal collaborations within the company, leveraging her clinical development expertise to advance Ipsen's vision of addressing challenging rare diseases. Martina Dempsey is the Vice President of Commercial Strategy & Operations at Astellas Europe, having worked with the business since 2014 in her home country of Ireland. In addition to her role at the pharma company, she also acts as a Board Member for the Irish Pharmaceutical Healthcare Association. Prior to her time at Astellas, she spent 13 years at GSK in various roles including in the regulatory affairs and business transformation sectors. Elias Revonta is the Founder and CEO, Orcason Medical, where he is supported by a strong background in the medical device industry – spanning over 20 years in various leadership roles from sales to product development. He is passionate about transforming and democratising healthcare with modern and easy-to-use diagnostic tools that serve all demographics.

In this final episode of the season, Isabel discusses how to normalise the conversation, not the suffering, around menopause with Dr Cecilia Caetano, Vice President, Head, Global Medical Affairs, Women's Health, Bayer. Menopause affects over 50% of the world's population, but its symptoms and effects are often misunderstood or ignored. Find out how industry can help by equipping not only HCPs but also women with the knowledge and awareness to manage menopause on an individual level, debunking the myths and prejudices surrounding the topic and much more.